Duvortuxizumab

Duvortuxizumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Janssen Pharmaceutica.

Mechanism of Action

Duvortuxizumab is a monoclonal antibody that targets the CD19 antigen, a protein expressed on the surface of B-cell lymphomas and leukemias. By binding to this antigen, duvortuxizumab can direct the body's immune system to destroy the cancer cells.

Clinical Trials

Duvortuxizumab has been tested in clinical trials for the treatment of Non-Hodgkin lymphoma and Acute lymphoblastic leukemia. The results of these trials have shown promise, but further research is needed to determine the drug's efficacy and safety profile.

Side Effects

Like all drugs, duvortuxizumab can cause side effects. The most common side effects reported in clinical trials include fever, fatigue, and nausea. More serious side effects can include infection, anemia, and neutropenia.

See Also

• Monoclonal antibodies
• Cancer treatment
• Janssen Pharmaceutica

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!